InsidersTradesSigma
Denali Therapeutics Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Denali Therapeutics Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Denali Therapeutics Inc. has recorded 264 public disclosures. Market capitalisation: €2.6bn. The latest transaction was reported on 8 January 2025 (Cession). Among the most active insiders: Schuth Alexander O.. The full history is openly available.
264
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€29m
162 ops.
Sell Volume
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 January 2025
Declarations264 total
12,255 shares@ US$20.224.1% of flowCommon StockSEC:0001714899-25-000050:0
29,266 shares@ US$20.226.8% of flowCommon StockSEC:0001714899-25-000049:0
3,339 shares@ US$20.811.6% of flowCommon StockSEC:0001714899-25-000048:0
54,180 shares0Common StockSEC:0001714899-25-000027:0
54,180 shares0Common StockSEC:0001714899-25-000028:0
30,000 shares@ US$20.2513.9% of flowCommon StockSEC:0001714899-25-000002:0
3,080 shares@ US$20.915.0% of flowCommon StockSEC:0001714899-25-000001:0
6,708 shares@ US$5.280.6% of flowCommon StockSEC:0001714899-24-000236:0
20,516 shares@ US$0.680.2% of flowCommon StockSEC:0001714899-24-000234:0
47,165 shares@ US$18.00100.0% of flowCommon StockSEC:0001714899-24-000219:0
1,020 shares@ US$30.002.3% of flowCommon StockSEC:0001714899-24-000217:0
15,558 shares@ US$5.281.3% of flowCommon StockSEC:0001714899-24-000218:0
3,080 shares@ US$27.076.1% of flowCommon StockSEC:0001714899-24-000208:0
40,000 shares@ US$0.680.3% of flowCommon StockSEC:0001714899-24-000206:0
30,000 shares@ US$29.0318.7% of flowCommon StockSEC:0001714899-24-000200:0
1,020 shares@ US$30.002.2% of flowCommon StockSEC:0001714899-24-000199:0
2,980 shares@ US$24.995.4% of flowCommon StockSEC:0001714899-24-000198:0
1,727 shares@ US$23.790.9% of flowCommon StockSEC:0001714899-24-000196:0
2,453 shares@ US$23.790.9% of flowCommon StockSEC:0001714899-24-000195:0
2,260 shares@ US$23.790.6% of flowCommon StockSEC:0001714899-24-000197:0
2,272 shares@ US$22.890.8% of flowCommon StockSEC:0001714899-24-000177:0
25 of 264 declarations
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a U.S.-based biopharmaceutical company headquartered in South San Francisco, California, and listed on the Nasdaq market (NYSE/NASDAQ). Founded in 2015, Denali was built around a focused scientific mission: to overcome the blood-brain barrier and enable delivery of therapeutics to the central nervous system. Its core asset is the proprietary TransportVehicle™ (TV) platform, which is designed to transport large therapeutic molecules such as enzymes, antibodies, and oligonucleotides across the blood-brain barrier after intravenous administration. This platform-led strategy makes Denali a differentiated player in the intersection of neurology, rare disease, and advanced biologics. ([denalitherapeutics.com](https://www.denalitherapeutics.com/about-us/)) Denali’s pipeline is concentrated in lysosomal storage disorders and neurodegenerative diseases, with a mix of clinical and earlier-stage programs. Its lead program is tividenofusp alfa (DNL310; ETV:IDS) for Hunter syndrome (MPS II), a next-generation enzyme replacement therapy that was supported by phase 1/2 clinical data and was under FDA priority review in early 2026. Denali also highlighted DNL126 for Sanfilippo syndrome type A, DNL628 for Alzheimer’s disease, DNL952 for late-onset Pompe disease, and additional TV-enabled and small-molecule programs. The company has stated that five TV-enabled programs are currently in clinical development. ([investors.denalitherapeutics.com](https://investors.denalitherapeutics.com/news-releases/news-release-details/new-england-journal-medicine-publishes-phase-12-study-denali)) From a competitive standpoint, Denali’s main differentiator is not simply a single drug candidate but a delivery technology intended to unlock whole-body and brain exposure for biologics. If clinically durable, this could create meaningful strategic value in diseases where standard therapies fail to address CNS pathology because they do not cross the blood-brain barrier. At the same time, the investment case remains typical of a late-stage biotech company: regulatory uncertainty, dependence on a small number of assets, execution risk in commercialization, and the need to manage capital efficiently. ([investors.denalitherapeutics.com](https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm)) The biggest recent development is the FDA approval of AVLAYAH™ (tividenofusp alfa-eknm) for Hunter syndrome in March 2026, a significant commercial and scientific validation of Denali’s platform. Management also flagged 2026 as a pivotal year, with expected data readouts across the pipeline and plans to advance programs into Alzheimer’s and Pompe disease studies. For investors, Denali is best understood as a platform biotech with a newly validated lead asset, substantial upside optionality, and the usual biotech risk profile tied to regulation, clinical execution, and launch performance. ([investors.denalitherapeutics.com](https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm))
